Vijaya Diagnostic Centre Limited has announced its audited financial results for the quarter and year ended March 31, 2026. The company achieved a strong performance, reporting a consolidated annual revenue of Rs. 81,420.19 lakhs and a profit after tax of Rs. 17,297.66 lakhs. Driven by this growth, the Board of Directors has recommended a dividend of Rs. 2 per equity share, representing a 200% payout for the financial year.
Annual Financial Performance
For the financial year ended March 31, 2026, Vijaya Diagnostic Centre reported consolidated revenue of Rs. 81,420.19 lakhs, marking significant growth compared to the previous year. The group’s consolidated net profit for the year stood at Rs. 17,297.66 lakhs, demonstrating robust operational efficiency. On a standalone basis, the company reported an annual revenue of Rs. 76,542.88 lakhs with a net profit of Rs. 17,831.03 lakhs.
Dividend Recommendation
Reflecting the company’s solid financial health and commitment to shareholder value, the Board of Directors has recommended a final dividend of Rs. 2 per equity share for the financial year 2025–26. This payout, amounting to 200% of the face value of the shares, is subject to approval by shareholders at the upcoming Annual General Meeting.
Strategic Developments
The company successfully completed the amalgamation of Medinova Diagnostic Services Limited with the parent entity effective April 1, 2024. This strategic consolidation was accounted for using the pooling of interest method, with all comparatives restated to reflect the merger. Furthermore, the company continues to manage its workforce obligations following the implementation of the new Labour Codes by the government, ensuring compliance and accurate provisioning for employee liabilities.
Operational Outlook
Vijaya Diagnostic Centre remains focused on its core business, operating as a single reportable segment centered on diagnostic services. With a strong cash position—reporting Rs. 3,967.52 lakhs in consolidated cash and cash equivalents at the end of the year—the company is well-positioned to continue its expansion strategy and maintain its leadership in the diagnostic healthcare space.
Source: BSE
